Back to News
Sep 22, 2025 4:00 PM

Roche Targets Top Spot In Weight Loss Drug Market

Roche Holdings AG (OTC:RHHBY) on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes competition with Eli Lilly And Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO).

The company announced it had advanced CT-388, its experimental obesity treatment, into a Phase 3 trial.

The therapy entered Roche's pipeline through its 2023 acquisition of Carmot Therapeutics.

RHHBY is demonstrating bullish strength. Follow the breaking news here.

In May 2024, Phase 1b data of CT-388 showed that a once-weekly subcutaneous injection of CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo. 

Also Read: New Obesity Drugs May ...